Liane M. Peterson is a first chair trial litigator with extensive experience handling IP litigation matters in U.S. district courts and before the U.S. International Trade Commission (ITC). She is co-chair of the firm’s IP Litigation Practice and a member of the Chemical, Biotechnology & Pharmaceutical Practice. Liane is also a member of the Life Sciences Industry Team as well as the Health Care & Life Sciences and Innovative Technology Sectors.
Liane focuses her practice on complex patent litigation in the pharmaceutical and biotechnology fields, with a particular focus on Hatch-Waxman litigation. She has represented numerous pharmaceutical, biologics, and life sciences companies in litigation at the district court and appellate levels across a wide range of matters involving small molecule drugs, biologics, medical devices, cosmetics, vaccines, and diagnostics. Liane also routinely counsels clients, including startups, and both large pharmaceutical companies and those engaged in early-stage clinical research on a range of pre-litigation matters.
Liane also has significant experience handling Section 337 patent litigation for clients at the ITC and routinely assists clients with a range of IP disputes, including licensing matters, trade secret misappropriation, unfair competition and antitrust claims.
Liane previously worked as a law clerk at the ITC in the Office of Unfair Import Investigations dealing with Section 337 investigations of unfair trade practices involving intellectual property rights. Prior to law school she served as a researcher at The Institute for Genomic Research in Rockville, Md.
代表经验
Pharmaceutical and Life Sciences Cases
- Allustra Technologies LLC v. Clarins USA, Inc., 1:22-cv-09948 (S.D.N.Y.)
- Trutek Corp. v. BlueWillow Biologics, Inc., 4:21-cv-10312 (E.D. Mich.)
- Ravgen, Inc. v. Myriad Genetics, Inc., 1:20-cv-01730 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. Natco Pharma Ltd., 1:19-cv-02368 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. MSN Laboratories Private Ltd., 1:19-cv-02342 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. Accord Healthcare Inc., 1:19-cv-02321 (D. Del.)
- Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialties Ltd., 1:19-cv-02309 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc., 1:18-cv-00758 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, 1:18-cv-00699 (D. Del.)
- NuGEN Technologies, Inc. v. Keygene NV, 4:18-cv-00525 (N.D. Cal.)
- Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC, 1:17-cv-01429 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Mylan Technologies Inc., et al., 1:15-cv-00328 (D. Del.)
- Noven Pharmaceuticals, Inc. v. Actavis Laboratories UT, Inc., 1:15-cv-00249 (D. Del.)
- Unimed Pharmaceuticals LLC, et al. v. Sandoz, Inc., 1:15-cv-01120 (D. Del.)
- Unimed Pharmaceuticals LLC, et al. v. Lupin Atlantis Holdings SA, 1:15-cv-00904 (D. Del.)
- AstraZeneca LP, et al. v. HEC Pharm Co., Ltd., 1:15-cv-01041 (D. Del.)
- Actavis Laboratories UT, Inc. v. Par Pharmaceutical, Inc., 1:15-cv-00886 (D. Del.)
- Sebela Pharmaceuticals v. Prinston Pharmaceutical, 2:14-cv-07400 (D.N.J.)
- Sebela Pharmaceuticals v. Actavis Laboratories FL, Inc., 2:14-cv-06414 (D.N.J.)
- Par Pharmaceutical, Inc. v. GlaxoSmithKline LLC and Aptalis Pharma, 1:14-cv-06627 (E.D. Pa.)
- AstraZeneca v. Sagent Pharmaceuticals, Inc. and Glenmark Pharmaceuticals Ltd., 1:14-cv-03547 (D.N.J.)
- Lyne Laboratories, Inc., et al. v. Lupin Ltd., 1:14-cv-10153 (D. Mass.)
- Unimed Pharmaceuticals LLC, et al. v. Perrigo Co., et al., 1:13-cv-00236 (D. Del.)
- Boehringer Ingelheim et al. v. Kremers Urban Pharmaceuticals Inc., 1:13-cv-01580 (D.N.J.)
- Keygene NV v. Floragenex Inc., 3:11-cv-00803 (D. Or.)
- Pfizer Inc. et al. v. Kremers Urban, LLC, et al. (D. Del.)
- Sepracor Inc. et al. v. Pharmaceutical Associates, Inc. (D.N.J.)
- Schering Corp. v. Geopharma, Inc. (D.N.J.)
- Sanofi-Aventis v. Ebewe Pharma (D.N.J.)
ITC Cases
- Certain Residential Premises Security Monitoring and Automation Control Panels, 337-TA-1273
- Certain Fitness Devices, 337-TA-1265
- Certain Wearable Monitoring Devices, 337-TA-1190
- Certain Semiconductor Devices, Semiconductor Device Packages, and Products Containing Same, 337-TA-1010
- Certain Computing or Graphics Systems, Components Thereof, and Vehicles Containing Same, Inv. No. 337-TA-984
- Certain Dental Implants, Inv. No. 337-TA-934
- Certain Integrated Circuits and Products Containing Same, Inv. No. 337-TA-920
- Certain Optoelectronic Devices for Fiber Optic Communications, Inv. No. 337-TA-860
- Certain Motion Sensitive Sound Effects Devices and Image Display Devices and Components and Products Containing Same, Inv. No. 337-TA-773
- Certain Buffer Systems and Components Thereof Used in Container Processing Lines, Inv. No. 337- TA-609
- Certain Lighting Control Devices Including Dimmer Switches and/or Switches and Parts Thereof, Inv. No. 337-TA-599
- Certain Shirts with Pucker-Free Seams and Methods of Producing Same, Inv. No. 337-TA-517
奖项与表彰
- IAM Patent 1000 – The World’s Leading Patent Practitioners (2025)
附属机构
- 美国律师协会会员
- Member, American Intellectual Property Association
- Member, International Trade Commission Trial Lawyers Association
- 联邦巡回法院律师协会成员
演讲和出版物
- “GLP-1 Receptor Agonists: Drug Litigation Overview and Trends,” Health Care Law Today (April 2, 2025)
- “Top Trends to Watch in Pharmaceutical Litigation,” Foley Health Care & Life Sciences Webinar (October 12, 2023)
- “U.S. Patent Litigation, including ITC, Hatch-Waxman and Biosimilar Litigation Proceedings,” presented with Lee & Ko and Korea Pharmaceutical and Bio-Pharma Manufacturers Association (September 26, 2023)
- “Statistics, Trends and Developments in Popular U.S. Patent Litigation Jurisdictions,” Japan Intellectual Property Association (September 27, 2023)
- “Timing Considerations for Section 337 Investigations and IPRs,” Bloomberg Law Professional Perspectives (October 13, 2022)
- “Hot Topics in U.S. Patent Litigation,” Winning in the Unknown – U.S. Intellectual Property Development Seminar Series (January 27, 2021)
- “Assessing the Limitations and Prospects of Obviousness-Type Double Patenting,” ACI Paragraph IV Disputes, New York (August 20-21, 2020)
- “Hatch-Waxman and BPCIA Fundamentals: Examining Follow-On Products and the Rules for Generic Entry,” ACI FDA Boot Camp, New York (March 23-25, 2020) (invited to speak; program cancelled)
- “Hot Topics on Patent Litigation,” 2019 Tokyo IP Conference (October 16, 2019)
- “Assessing Secondary Considerations in Light of Blocking Patents Post-Acorda,” ACI Paragraph IV Disputes, New York (April 29-30, 2019)
- “Latest Patent Litigation and IPR Considerations for Japanese Companies” and “USITC As Successful Venue for Patent Owners,” 2018 Tokyo IP Conference (October 11, 2018)
- “Deciphering the Business Implications of the On-Sale Bar,” ACI Paragraph IV Disputes, New York (April 23-24, 2018)
- “Hatch-Waxman Year-in-Review Panel,” ABA IP Law Section Annual Conference (April 7, 2016)
- “e-Discovery in U.S. Patent Litigation,” Advanced U.S. Patent Litigation Seminar Series, Osaka, Japan and Tokyo, Japan (January 27-28, 2016)
- “Beginning the Litigation: Initial Considerations and Strategies,” U.S. Patent Litigation Seminar Series, Osaka, Japan (May 15, 2014)
- Hatch-Waxman Litigation Seminar, Japan Pharmaceutical Manufacturers Association IP Committee, Tokyo, Japan (May 12, 2014)
- “Expert Discovery, Markman Hearings & Preparing for Trial,” U.S. Patent Litigation Seminar Series, Tokyo, Japan (November 14, 2013)
- “Motions for Summary Judgment, Attorney-Client Privilege and ITC Practice,” U.S. Patent Litigation Seminar Series, Tokyo, Japan (September 12, 2013)
- “Managing E-Discovery in U.S. Patent Litigation,” AIPPI Journal in Japan, Vol. 54, No. 10, 2009
- “Duty of Disclosure Requirements: Best Practice for Handling and Managing Disclosure Requirements,” TACPI D.C. Round Table Seminar (December 18, 2009)
- “Practical Steps to Address E-Discovery: New Battleground in U.S. IP Litigation,” TACPI D.C. Round Table Seminar (August 27, 2009)
- “Strategic Document Management for Corporate IP Practitioners,” presented to NGB and clients in Japan (May 19, 2009)
- “Proper Scope of ITC Remedies After Qualcomm,” IP Law360 (October 22, 2008)
最值得关注的制药诉讼趋势
随着医疗保健和生命科学行业的不断发展，全国各地的组织机构都应关注医药诉讼的最新趋势。无论是防锈、知识产权、大规模侵权诉讼，还是其他诉讼问题，本次网络研讨会都将深入探讨该行业正在兴起的制药趋势。
GLP-1药物聚焦：趋势、需求与未来展望
福莱国际医疗健康与生命科学及创新技术业务部诚邀您参加网络研讨会，探讨贵机构如何在GLP-1类药物发展的十字路口把握机遇，为不断演变的行业格局做好准备。
Foley 代表 Verona Pharma 参与默克公司价值 100 亿美元的收购案
Foley & Lardner LLP 律师事务所担任英国维罗纳制药公司（Verona Pharma）的美国知识产权法律顾问，该公司是一家专注于呼吸系统疾病的生物制药公司，被默克公司（Merck & Co.Inc.（默克公司）约 100 亿美元的收购案中担任该公司的美国知识产权法律顾问。
IAM在2025年版《IAM专利1000：世界领先专利从业者》中表彰富理达律师和司法管辖区
Foley & Lardner LLP 的 17 名律师和 5 个司法辖区入选 2025 年版《IAM Patent 1000：世界领先专利从业者》（IAM Patent 1000: The World's Leading Patent Practitioners）。
GLP-1受体激动剂：药物诉讼概述与趋势
近期，用于治疗体重减轻和肥胖的GLP-1类药物因其效果提升和受欢迎程度上升，导致美国涉及该类药物的诉讼案件数量增加。
2024 福来东京知识产权会议
请参加9月25日星期三举行的2024年富理达东京知识产权会议--"创新业务导航：关于专利资格、人工智能和其他重要知识产权发展的见解"--为期半天的教育研讨会将引导您了解最新的知识产权法律发展及其对美国商业的实际影响。